{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:01:57Z","timestamp":1780470117980,"version":"3.54.1"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Therapeutic monoclonal antibodies (mAbs) show great promise for treating neurological disorders thanks to their high selectivity and potency. However, their clinical potential is significantly limited by poor penetration across the blood-brain barrier (BBB). It has been shown that antibodies targeting transferrin receptor 1 (TfR1) can reach the brain after peripheral administration. In addition, human H-ferritin (HFn) naturally undergoes TfR1-mediated transcytosis, making it a compelling alternative candidate platform for brain-directed drug delivery. This study evaluates the feasibility of using HFn as a generic shuttle to transport therapeutic antibodies into the brain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      An anti-BACE1 monoclonal antibody (1A11) was chemically conjugated to HFn, and the resulting nanoparticles (1A11-HFn NPs) were assessed\n                      <jats:italic>in vitro<\/jats:italic>\n                      and\n                      <jats:italic>in vivo<\/jats:italic>\n                      for their structural integrity, target binding, BBB permeability, BACE1 inhibition, and pharmacological effects. Hereto, HFn and the mAb 1A11 were produced in\n                      <jats:italic>Escherichia coli<\/jats:italic>\n                      and CHO cells, respectively, followed by purification of each protein. Conjugation of 1A11 to HFn was achieved using the heterobifunctional linker NHS-PEG-Mal, after which 1A11-HFn NPs were isolated. Binding to human BACE1 and human TfR1 was confirmed. Structural characterization was performed via transmission electron microscopy (TEM). Pharmacokinetics (PK) and pharmacodynamics (PD) were examined in humanized apical domain TfR1 knock-in (hApiTfrc KI) mice after intravenous (IV) administration, with evaluation of both plasma and brain tissue.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      1A11-HFn NPs were successfully generated with confirmed dual binding to hBACE1 and hTfR1. TEM imaging verified the structural integrity of the nanoparticles.\n                      <jats:italic>In vivo<\/jats:italic>\n                      studies demonstrated increased brain levels of 1A11-HFn NPs at days 1 and 3 post-administration, though levels declined below the limit of detection (LOD) by day 7. The amount reaching the brain at day 1 but not day 3 or 7 was sufficient to inhibit BACE1 activity, indicating a pharmacological meaningful dose could reach the brain after peripheral administration.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings demonstrate that HFn can serve as an effective shuttle to deliver mAbs across the BBB at pharmacologically relevant concentrations. This work provides foundational evidence supporting HFn-based nanoparticles as a promising platform for brain-targeted delivery of biological therapeutics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnagi.2026.1839772","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:05:43Z","timestamp":1780466743000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["H-ferritin nanoparticle-mediated antibody delivery across the blood-brain barrier"],"prefix":"10.3389","volume":"18","author":[{"given":"Ziwei","family":"Yuan","sequence":"first","affiliation":[{"name":"Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven \u2013 University of Leuven","place":["Leuven, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ru\u00e9","sequence":"additional","affiliation":[{"name":"Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven \u2013 University of Leuven","place":["Leuven, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Jaspers","sequence":"additional","affiliation":[{"name":"Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven \u2013 University of Leuven","place":["Leuven, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Lynn","family":"Cuypers","sequence":"additional","affiliation":[{"name":"Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven \u2013 University of Leuven","place":["Leuven, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Dewilde","sequence":"additional","affiliation":[{"name":"Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven \u2013 University of Leuven","place":["Leuven, Belgium"]},{"name":"PharmAbs, The KU Leuven Antibody Center, KU Leuven \u2013 University of Leuven","place":["Leuven, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/0006-291x(75)90676-2","article-title":"Multiple subunits in human ferritins: Evidence for hybrid molecules.","volume":"63","author":"Adelman","year":"1975","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B2","doi-asserted-by":"publisher","first-page":"6564585","DOI":"10.1155\/2021\/6564585","article-title":"Blood-brain barrier overview: Structural and functional correlation.","volume":"2021","author":"Alahmari","year":"2021","journal-title":"Neural Plast."},{"key":"B3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/jcph.1545","article-title":"Concept of pharmacologic target-mediated drug disposition in large-molecule and small-molecule compounds.","volume":"60","author":"An","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41531-025-01117-6","article-title":"A brain-shuttled antibody targeting alpha synuclein aggregates for the treatment of synucleinopathies.","volume":"11","author":"An","year":"2025","journal-title":"NPJ Parkinsons Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery.","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1021\/acs.molpharmaceut.6b00456","article-title":"Very high plasma concentrations of a monoclonal antibody against the human insulin receptor are produced by subcutaneous injection in the rhesus monkey.","volume":"13","author":"Boado","year":"2016","journal-title":"Mol. Pharm."},{"key":"B7","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/s0092-8674(04)00130-8","article-title":"Structure of the human transferrin receptor-transferrin complex.","volume":"116","author":"Cheng","year":"2004","journal-title":"Cell"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5053","DOI":"10.1038\/s41467-023-40681-4","article-title":"CD98hc is a target for brain delivery of biotherapeutics.","volume":"14","author":"Chew","year":"2023","journal-title":"Nat. Commun."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3946320231209839","DOI":"10.1177\/03946320231209839","article-title":"Novel anti-amyloid-beta (Abeta) monoclonal antibody lecanemab for Alzheimer\u2019s disease: A systematic review.","volume":"37","author":"Chowdhury","year":"2023","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1126\/scitranslmed.3005338","article-title":"Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier.","volume":"5","author":"Couch","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12987-025-00624-1","article-title":"Increasing brain half-life of antibodies by additional binding to myelin oligodendrocyte glycoprotein, a CNS specific protein.","volume":"22","author":"Cuypers","year":"2025","journal-title":"Fluids Barriers CNS"},{"key":"B12","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nnano.2012.90","article-title":"Magnetoferritin nanoparticles for targeting and visualizing tumour tissues.","volume":"7","author":"Fan","year":"2012","journal-title":"Nat. Nanotechnol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1021\/acsnano.7b06969","article-title":"Ferritin nanocarrier traverses the blood brain barrier and kills glioma.","volume":"12","author":"Fan","year":"2018","journal-title":"ACS Nano"},{"key":"B14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1021\/nn900002m","article-title":"Impact of nanotechnology on drug delivery.","volume":"3","author":"Farokhzad","year":"2009","journal-title":"ACS Nano"},{"key":"B15","doi-asserted-by":"publisher","first-page":"100986","DOI":"10.1016\/j.bbih.2025.100986","article-title":"Cardiovascular health and its association with dementia, Parkinson\u2019s disease, and mortality among UK older adults.","volume":"45","author":"Georgescu","year":"2025","journal-title":"Brain Behav. Immun. Health"},{"key":"B16","doi-asserted-by":"publisher","first-page":"10938","DOI":"10.3390\/ijms222010938","article-title":"Enzyme replacement therapy with pabinafusp alfa for neuronopathic mucopolysaccharidosis II: An integrated analysis of preclinical and clinical data.","volume":"22","author":"Giugliani","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","article-title":"The amyloid-beta pathway in Alzheimer\u2019s disease.","volume":"26","author":"Hampel","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.3390\/ijms23084153","article-title":"Crossing the blood-brain barrier: Advances in nanoparticle technology for drug delivery in neuro-oncology.","volume":"23","author":"Hersh","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1021\/cr5004908","article-title":"Unity in the biochemistry of the iron-storage proteins ferritin and bacterioferritin.","volume":"115","author":"Honarmand Ebrahimi","year":"2015","journal-title":"Chem. Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"eadr9266","DOI":"10.1126\/sciadv.adr9266","article-title":"Bioengineered protein nanocarrier facilitating siRNA escape from lysosomes for targeted RNAi therapy in glioblastoma.","volume":"11","author":"Jin","year":"2025","journal-title":"Sci. Adv."},{"key":"B21","doi-asserted-by":"publisher","first-page":"7777","DOI":"10.1021\/acsami.7b18304","article-title":"Morphology and magnetic structure of the ferritin core during iron loading and release by magnetooptical and NMR methods.","volume":"10","author":"Koralewski","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1073\/pnas.0913192107","article-title":"Binding and uptake of H-ferritin are mediated by human transferrin receptor-1.","volume":"107","author":"Li","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"B23","doi-asserted-by":"publisher","first-page":"14900","DOI":"10.1073\/pnas.1407808111","article-title":"H-ferritin-nanocaged doxorubicin nanoparticles specifically target and kill tumors with a single-dose injection.","volume":"111","author":"Liang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1073\/pnas.97.4.1456","article-title":"Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein.","volume":"97","author":"Lin","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"B25","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jconrel.2019.12.010","article-title":"Target delivering paclitaxel by ferritin heavy chain nanocages for glioma treatment.","volume":"323","author":"Liu","year":"2020","journal-title":"J. Control Release"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases.","volume":"27","author":"Lu","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/abt\/tbac021","article-title":"The global landscape of approved antibody therapies.","volume":"5","author":"Lyu","year":"2022","journal-title":"Antib. Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nature13148","article-title":"Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy.","volume":"509","author":"Mancias","year":"2014","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","first-page":"238428","DOI":"10.1155\/2013\/238428","article-title":"Nanoparticles for brain drug delivery.","volume":"2013","author":"Masserini","year":"2013","journal-title":"ISRN Biochem."},{"key":"B30","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery.","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"B31","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/nrd4363","article-title":"Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies.","volume":"13","author":"Mitragotri","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/s41467-019-09098-w","article-title":"Cryo-EM structure of the human ferritin-transferrin receptor 1 complex.","volume":"10","author":"Montemiglio","year":"2019","journal-title":"Nat. Commun."},{"key":"B33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","article-title":"The blood-brain barrier: Bottleneck in brain drug development.","volume":"2","author":"Pardridge","year":"2005","journal-title":"NeuroRx"},{"key":"B34","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3389\/fnagi.2019.00373","article-title":"Blood-brain barrier and delivery of protein and gene therapeutics to brain.","volume":"11","author":"Pardridge","year":"2019","journal-title":"Front. Aging Neurosci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12951-018-0392-8","article-title":"Nano based drug delivery systems: Recent developments and future prospects.","volume":"16","author":"Patra","year":"2018","journal-title":"J. Nanobiotechnol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/bs.apha.2014.06.001","article-title":"Transcytosis of macromolecules at the blood-brain barrier.","volume":"71","author":"Preston","year":"2014","journal-title":"Adv. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/joim.13440","article-title":"The influence of the blood-brain barrier in the treatment of brain tumours.","volume":"292","author":"Rathi","year":"2022","journal-title":"J. Intern. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1039\/d0bm01726d","article-title":"H-Ferritin nanoparticle-mediated delivery of antibodies across a BBB in vitro model for treatment of brain malignancies.","volume":"9","author":"Rizzuto","year":"2021","journal-title":"Biomater. Sci."},{"key":"B39","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: The neonatal Fc receptor comes of age.","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.3390\/pharmaceutics15061748","article-title":"Novel human\/non-human primate cross-reactive anti-transferrin receptor nanobodies for brain delivery of biologics.","volume":"15","author":"Rue","year":"2023","journal-title":"Pharmaceutics"},{"key":"B41","doi-asserted-by":"publisher","first-page":"106934","DOI":"10.1016\/j.phrs.2023.106934","article-title":"Ferritin nanoconjugates guide trastuzumab brain delivery to promote an antitumor response in murine HER2 + breast cancer brain metastasis.","volume":"196","author":"Sevieri","year":"2023","journal-title":"Pharmacol. Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces Abeta plaques in Alzheimer\u2019s disease.","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: Progress, challenges and opportunities.","volume":"17","author":"Shi","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"B44","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3390\/cells10020328","article-title":"Selective targeting of cancer-associated fibroblasts by engineered H-ferritin nanocages loaded with navitoclax.","volume":"10","author":"Sitia","year":"2021","journal-title":"Cells"},{"key":"B45","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","article-title":"Strategies for delivering therapeutics across the blood-brain barrier.","volume":"20","author":"Terstappen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"B46","doi-asserted-by":"publisher","first-page":"14933","DOI":"10.1002\/anie.201708530","article-title":"Enzyme encapsulation by a ferritin cage.","volume":"56","author":"Tetter","year":"2017","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"B47","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nrd4333","article-title":"Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery.","volume":"13","author":"Torchilin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"B48","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.bioactmat.2022.02.026","article-title":"Targeted delivery of a STING agonist to brain tumors using bioengineered protein nanoparticles for enhanced immunotherapy.","volume":"16","author":"Wang","year":"2022","journal-title":"Bioact. Mater."},{"key":"B49","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1021\/acs.biomac.7b01545","article-title":"Extending half life of H-ferritin nanoparticle by fusing albumin binding domain for doxorubicin encapsulation.","volume":"19","author":"Wang","year":"2018","journal-title":"Biomacromolecules"},{"key":"B50","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jbiotec.2017.05.025","article-title":"High hydrostatic pressure encapsulation of doxorubicin in ferritin nanocages with enhanced efficiency.","volume":"254","author":"Wang","year":"2017","journal-title":"J. Biotechnol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/nmat1737","article-title":"Co-delivery of drugs and DNA from cationic core\u2013shell nanoparticles self-assembled from a biodegradable copolymer.","volume":"5","author":"Wang","year":"2006","journal-title":"Nat. Mater."},{"key":"B52","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12987-022-00374-4","article-title":"VHHs as tools for therapeutic protein delivery to the central nervous system.","volume":"19","author":"Wouters","year":"2022","journal-title":"Fluids Barriers CNS"},{"key":"B53","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3390\/pharmaceutics13040521","article-title":"Engineered human heavy-chain ferritin with half-life extension and tumor targeting by PAS and RGDK peptide functionalization.","volume":"13","author":"Yin","year":"2021","journal-title":"Pharmaceutics"},{"key":"B54","doi-asserted-by":"publisher","first-page":"261ra154","DOI":"10.1126\/scitranslmed.3009835","article-title":"Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates.","volume":"6","author":"Yu","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"101564","DOI":"10.1016\/j.nantod.2022.101564","article-title":"Constructing a nanocage-based universal carrier for delivering TLR-activating nucleic acids to enhance antitumor immunotherapy.","volume":"46","author":"Zhang","year":"2022","journal-title":"Nano Today"},{"key":"B56","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1038\/s41467-026-70383-6","article-title":"Bioengineered ferritin-based lysosome-targeting chimera platform for tumor-targeted therapy.","volume":"17","author":"Zhang","year":"2026","journal-title":"Nat. Commun."},{"key":"B57","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1093\/abt\/tbac028","article-title":"Engineering antibody and protein therapeutics to cross the blood-brain barrier.","volume":"5","author":"Zhao","year":"2022","journal-title":"Antib. Ther."},{"key":"B58","doi-asserted-by":"publisher","first-page":"4830","DOI":"10.1021\/nn305791q","article-title":"RGD-modified apoferritin nanoparticles for efficient drug delivery to tumors.","volume":"7","author":"Zhen","year":"2013","journal-title":"ACS Nano"},{"key":"B59","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.neuron.2015.11.024","article-title":"Discovery of novel blood-brain barrier targets to enhance brain uptake of therapeutic antibodies.","volume":"89","author":"Zuchero","year":"2016","journal-title":"Neuron"}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1839772\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:05:44Z","timestamp":1780466744000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1839772\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":59,"alternative-id":["10.3389\/fnagi.2026.1839772"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2026.1839772","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"article-number":"1839772"}}